Lumos Diagnostics (ASX:LDX), a leader in rapid point-of-care (POC) diagnostic technologies, today announced that Jerome Adams, MD, MPH, will serve as a Strategic Healthcare Adviser to Lumos and will be appointed to the Company’s Medical Advisory Board. From 2017 to 2021, Dr. Adams served as the 20th Surgeon General of the United States.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210914005328/en/

Jerome Adams, MD, MPH (Photo: Business Wire)

As the immediate former U.S. Surgeon General, Dr. Adams brings a real-world public health perspective to the ongoing impact of global issues such as antimicrobial resistance and COVID-19. Utilizing his robust knowledge of public health, public policy and health equity, Dr. Adams will advise Lumos on the effective deployment of its POC diagnostic technologies, beginning with the launch of the FebriDx® test in approved markets. FebriDx is a novel fingerstick blood test that can differentiate if a person has a bacterial or viral infection, which often have overlapping signs and symptoms, within 10 minutes. The patented, dual biomarker FebriDx test is approved for sale in Europe, the UK, Canada and Australia and is currently under review for sale in the U.S.

“The pressing health challenges of the last 18 months have highlighted the importance of diagnostic testing as one of the key tools to fight both the current pandemic as well as the looming pandemic of antimicrobial resistance,” said Jerome Adams, MD, MPH. “We need to get ahead of these problems with a truly accessible outpatient solution. By measuring a patient’s immune system response in addition to assessing symptoms, clinicians can quickly determine if the patient has a bacterial infection requiring antibiotics, a viral infection that may benefit from additional confirmatory testing, or no infection that allows a safe return to school or work – all while reducing unnecessary antibiotics.”

Performance from a prospective multi-center U.S. clinical trial demonstrates the FebriDx test’s high accuracy, with a 95% sensitivity to identify bacterial infection and 99% negative predictive value (NPV) to rule out bacterial infection. Outcome studies show that FebriDx can alter clinical management decisions in 48% of patients tested and may reduce unnecessary antibiotic prescriptions by approximately 80%. Further, the test has been shown to have a 99% NPV to rule out symptomatic COVID-19 infection, making it an ideal rapid triage test. FebriDx viral positive patients may be confirmed as COVID-19 with a molecular or rapid antigen test including the Lumos CoviDx™ test. Using FebriDx as an initial testing strategy provides a cost-effective approach to managing outpatient respiratory infections.

Rob Sambursky, MD, Lumos President and Chief Executive Officer stated, “Lumos has found a match in our passion for public health in Dr. Adams. Together, we intend to make a meaningful impact for millions of patients each year by improving global access to innovative, cost-effective rapid diagnostic test solutions.”

As Surgeon General, Dr. Adams oversaw 6,500 uniformed health officers in nearly 600 locations around the world serving to promote, protect and advance health and safety. In addition to serving on the frontline of the U.S. response to the COVID-19 pandemic, as Surgeon General Dr. Adams worked to combat the opioid epidemic, rising rates of chronic disease, the impacts of rising suicide rates, promoted maternal health and helped businesses become better stewards and stakeholders in promoting community health and equitable access to healthcare resources. Dr. Adams currently serves as assistant professor of clinical anesthesia at Indiana University and practices as a staff anesthesiologist at Eskenazi Health.

This announcement is authorized for release to the market by the Lumos Disclosure Committee.

About Lumos Diagnostics

Lumos Diagnostics specializes in rapid, cost-effective and complete point-of-care (POC) diagnostic test technology to help healthcare professionals more accurately diagnose and manage medical conditions. Lumos offers customized assay development and manufacturing services for POC tests and proprietary digital reader platforms. Lumos also directly develops, manufactures and commercializes novel Lumos-branded POC tests that target infectious and inflammatory diseases.

For more information on Lumos Diagnostics, visit lumosdiagnostics.com, and for more information on FebriDx, visit febridx.com.

Media Contact (U.S. and Global): Jennifer Christiansen – Lumos Diagnostics jennifer.christiansen@lumosdiagnostics.com +1 920 784 3153 +1 941 928 9025

Media Contact (Australia): Haley Chartres – H^CK haley@hck.digital +61 423 139 163

Investor Contact: Matthijs Smith – Lumos Diagnostics ir@lumosdiagnostics.com +61 411 137 080 +61 3 9087 1598

Company Registered Office: Lumos Diagnostics Holdings Ltd Level 4, 100 Albert Rd South Melbourne, VIC 3205 +61 3 9087 1598

Lumos Diagnostics (ASX:LDX)
Historical Stock Chart
From Nov 2024 to Dec 2024 Click Here for more Lumos Diagnostics Charts.
Lumos Diagnostics (ASX:LDX)
Historical Stock Chart
From Dec 2023 to Dec 2024 Click Here for more Lumos Diagnostics Charts.